Global Benign Prostatic Hyperplasia Treatment Market (2021 to 2026) – Emerging Markets and Promising Product Pipeline Presents Opportunities – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Benign Prostatic Hyperplasia Treatment Market by Type (Drug (Alpha Blockers(Tamsulosin, Doxazosin), 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride), Surgical Treatment (TURP, TUMT, TUNA)), End User (Hospitals) – Global Forecast to 2026” report has been added to ResearchAndMarkets.com’s offering.
The global benign prostatic hyperplasia treatment market is projected to reach USD 14.1 billion by 2026 from USD 10.8 billion in 2021, at a CAGR of 5.3% from 2021 to 2026.
The growth of this market is driven owing to the increasing prevalence of benign prostatic hyperplasia, the rising preference for minimally invasive surgeries, increasing obesity rate, and investments, funds, and grants for research in the field of BPH treatment. Also, the emerging markets and promising product pipeline is anticipated to offer an opportunity for the growth of the market during the forecast period.
Drug treatment is expected to hold the largest share of the benign prostatic hyperplasia treatment market, by type in 2021.
Based on the type, the BPH treatment market is segmented into drug treatment and surgical treatment. Drug treatment is the largest and the fastest-growing segment in this market. This can primarily be attributed to the use of medications as the first line of treatment among men with mild to moderate symptoms of BPH.
Home healthcare is expected to hold the largest share of the benign prostatic hyperplasia treatment market, in 2021.
Based on the end user, the market is segmented into home healthcare and hospitals & clinics. In 2019, home healthcare accounted for the largest share of this market, as most patients are prescribed medications over surgery. Patients are also advised to continue taking medications for a few weeks post-surgery and may even require catheters for a few days. As a result, the emphasis in his market is skewed toward home healthcare over hospital care.
North America commanded the largest share of the benign prostatic hyperplasia treatment market in 2021.
On the basis of region, the benign prostatic hyperplasia treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2019, North America commanded the largest share of the benign prostatic hyperplasia treatment market. The large share of this market segment can be attributed to the rising geriatric and obese population and the availability of research funding are the major factors driving the market growth. Initiatives by key players are also expected to contribute to the market.
Market Dynamics
Drivers
- Increasing Prevalence of Benign Prostatic Hyperplasia
- Increasing Obesity
- Rising Preference for Minimally Invasive Surgeries
- Investments, Funds, and Grants for Research in BPH Treatment
- Availability of Reimbursement for Surgeries
Restraints
- Side-Effects Associated with BPH Medications
Opportunities
- Emerging Markets
- Promising Product Pipeline
Challenges
- Low Awareness Regarding Prostate Health Among Men
- Product Recalls in the BPH Treatment Market
Companies Mentioned
- Abbott Laboratories
- Advin Health Care
- Alembic
- Allergan
- Allium Ltd
- Asahi Kasei Corporation
- Asclepion Laser Technologies GmbH
- Astellas Pharma
- Biolitec Ag
- Boston Scientific Corporation
- Coloplast Group
- Eli Lilly and Company
- GlaxoSmithKline
- IPG Photonics Corporation
- Karl Storz Se & Co. Kg
- Lumenis Ltd.
- Medifocus Inc.
- Merck
- Olympus Corporation
- Pfizer
- Pharex Health Corp
- PNN Medical A/S
- Quanta System
- Richard Wolf GmbH
- SRS Medical
- Surgical Lasers Inc.
- Teleflex Incorporated
- Unilab, Inc.
- Urologix, LLC.
For more information about this report visit https://www.researchandmarkets.com/r/sr8fbm
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
